企業を読み込み中
Just reported
Q3 2026 results
From Neuropace's results release of 2026年11月12日. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Revenue
Actual
$23.1M
-16% y/y
+1.2% q/qGuided
—
No guide given
Operating income, adjusted
Actual
$400K
Guided
—
No guide given
Company outlook
Full year 2026
- Revenue$91M – $92M-8.5% y/y Lowered -9.0%
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Neuropace is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Devices
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plc$131.6BA+
SYKStryker Corp.$117.9BA+
EWEdwards Lifesciences Corporation$61.6BA+
GEHCGE Healthcare Technologies Inc.$37.5BA
GKOSGlaukos Corp$14.5BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A- EWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now A
- GEHCGE Healthcare Technologies Inc.2026年10月28日CAGraded C, now A
Neuropace, Inc. 自身が米国証券取引委員会（SEC）に提出した書類にもとづきます。数字は報告されたままで、1 株当たりの履歴は今日の株数基準に修正済みです。 これは事業の説明です——投資助言ではなく、売買を勧めるものでもありません。
